Penumbra Inc (PEN) stock

PENNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 15/3073% above fair value

$318.95−3.02 (-0.94%)

Close on Oct 30, 2026Market cap $12.56BP/E 80.3Yield –

Earnings

Penumbra's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Feb 24, 2027

Q4 FY2026 · estimated, during market hours

Revenue, Q3 FY2026

$410.10M

+15.6% on a year earlier

Adjusted EPS, Q3 FY2026

$1.07

$0.97 a year earlier

Latest guidance

Reaffirmed

Nov 5, 2025 · 1 item

Quarterly results

Revenue and earnings per share from each of Penumbra's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Adj. EPS	Source
Q4 FY2026ended Dec 31, 2026	Feb 24, 2027Expected	–	–	–	–	–
Q3 FY2026ended Sep 30, 2026	Oct 29, 2026after the close	$410.10M	+15.6%	$1.07	–	Release
Q2 FY2026ended Jun 30, 2026	Jul 30, 2026after the close	$390.00M	+14.9%	$0.88	–	Release
Q1 FY2026ended Mar 31, 2026	May 6, 2026after the close	$374.80M	+15.6%	$0.82	–	Release
Q4 FY2025ended Dec 31, 2025	Feb 25, 2026during market hours	$385.40M	+22.2%	$1.20	$1.18	Release
Q3 FY2025ended Sep 30, 2025	Nov 5, 2025after the close	$354.70M	+17.8%	$1.17	$0.97	Release
Q2 FY2025ended Jun 30, 2025	Jul 29, 2025after the close	$339.50M	+13.4%	$1.15	$0.86	Release
Q1 FY2025ended Mar 31, 2025	Apr 23, 2025after the close	$324.10M	+16.3%	$1.00	$0.83	Release
Q4 FY2024ended Dec 31, 2024	Feb 18, 2025after the close	$315.50M	+10.8%	$0.86	$0.97	Release
Q3 FY2024ended Sep 30, 2024	Oct 30, 2024after the close	$301.00M	+11.1%	$0.75	$0.85	Release
Q2 FY2024ended Jun 30, 2024	Jul 30, 2024after the close	$299.40M	+14.5%	-$1.55	$0.64	Release
Q1 FY2024ended Mar 31, 2024	May 7, 2024after the close	$278.70M	+15.5%	$0.28	$0.41	Release
Q4 FY2023ended Dec 31, 2023	Feb 22, 2024after the close	$284.70M	+28.7%	$1.38	$0.76	Release
Q3 FY2023ended Sep 30, 2023	Nov 2, 2023after the close	$270.90M	+26.8%	$0.23	$0.67	Release
Q2 FY2023ended Jun 30, 2023	Aug 1, 2023after the close	$261.50M	+25.5%	$0.48	$0.43	Release
Q1 FY2023ended Mar 31, 2023	May 2, 2023after the close	$241.40M	+18.4%	$0.22	$0.23	Release
Q4 FY2022ended Dec 31, 2022	Feb 23, 2023after the close	$221.20M	+8.4%	$0.10	$0.16	Release
Q3 FY2022ended Sep 30, 2022	Nov 3, 2022after the close	$213.70M	+12.4%	-$0.06	$0.01	Release
Q2 FY2022ended Jun 30, 2022	Aug 5, 2022after the close	$208.30M	–	-$0.10	$0.01	Release
Q1 FY2022ended Mar 31, 2022	May 3, 2022after the close	$203.90M	–	$0.00	-$0.01	Release
Q4 FY2021ended Dec 31, 2021	Feb 22, 2022after the close	$204.00M	–	-$0.66	$0.10	Release
Q3 FY2021ended Sep 30, 2021	Nov 3, 2021after the close	$190.10M	–	$0.24	$0.12	Release
Q2 FY2021ended Jun 30, 2021	Aug 9, 2021after the close	–	–	–	–	Filing
Q1 FY2021ended Mar 31, 2021	May 4, 2021after the close	–	–	–	–	Filing
Q4 FY2020ended Dec 31, 2020	Feb 23, 2021after the close	–	–	–	–	Filing
Q3 FY2020ended Sep 30, 2020	Oct 28, 2020after the close	–	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Penumbra guided for has been reported

Guidance vs results

The last range Penumbra gave before each report, against the figure it then reported. Full years add up the four quarters.

Period	Metric	Guidance	Actual	Result
FY2025	Revenue growth	+13% – +15%	+17.5%Σ4Q	Above range
Q4 FY2023	Revenue growth	+28% – +31%	+28.71%	Within range

Guidance history

Every forecast Penumbra put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Nov 5, 2025	U.S. Thrombectomy growth	FY2025	+20% – +21%	Reaffirmed
Jul 29, 2025	U.S. Thrombectomy growth	FY2025	+20% – +21%	New
Jul 29, 2025	total revenue growth	FY2025	+13% – +15%	New
Apr 23, 2025	operating margin expansion	FY2025	13% – 14%	Reaffirmed
Apr 23, 2025	U.S. Thrombectomy franchise growth	FY2025	+20% – +21%	Raised
Apr 23, 2025	total revenue	FY2025	$1.34B – $1.36B	Reaffirmed
Feb 18, 2025	operating margin expansion	FY2025	13% – 14%	New
Feb 18, 2025	U.S. thrombectomy franchise will grow	FY2025	+19% – +20%	New
Feb 18, 2025	year over year growth	FY2025	+12% – +14%	New
Feb 18, 2025	total revenue	FY2025	$1.34B – $1.36B	New
Oct 30, 2024	U.S. thrombectomy franchise	FY2024	+24% – +25%	New
Oct 30, 2024	total revenue	FY2024	$1.18B – $1.20B	Reaffirmed
Jul 30, 2024	non-GAAP gross margin expansion	FY2024	100 – 150	New
Jul 30, 2024	non-GAAP operating margin expansion	FY2024	100 – 200	Reaffirmed
Jul 30, 2024	U.S. thrombectomy growth	FY2024	+23% – +25%	Lowered
Jul 30, 2024	total revenue	FY2024	$1.18B – $1.20B	Lowered
May 7, 2024	gross margin expansion	FY2024	100 – 150	Reaffirmed
May 7, 2024	total non-GAAP operating margin expansion	FY2024	100 – 200	Reaffirmed
May 7, 2024	U.S. thrombectomy franchise	FY2024	+27% – +30%	Reaffirmed
May 7, 2024	total revenue	FY2024	$1.23B – $1.27B	Reaffirmed
Feb 22, 2024	gross margin expansion	FY2024	100 – 150	New
Feb 22, 2024	total non-GAAP operating margin expansion	FY2024	100 – 200	New
Feb 22, 2024	U.S. thrombectomy franchise	FY2024	+27% – +30%	New
Feb 22, 2024	total revenue	FY2024	$1.23B – $1.27B	New
Nov 2, 2023	total company revenue growth	Q4 FY2023	+28% – +31%	New
Nov 2, 2023	revenue	FY2023	$1.05B – $1.07B	Reaffirmed
Aug 1, 2023	total revenue	FY2023	$1.05B – $1.07B	Raised
May 2, 2023	total revenue	FY2023	$1.04B – $1.06B	Raised
Feb 23, 2023	total revenue	FY2023	$1.00B	Reaffirmed
Nov 3, 2022	constant currency	FY2022	+15% – +16%	Lowered
Nov 3, 2022	total revenue	FY2022	$840.00M – $845.00M	New
Nov 3, 2022	total revenue	FY2023	$1.00B	New
Aug 5, 2022	growth over 2021 revenue on a constant currency basis	FY2022	+15% – +17%	New
Aug 5, 2022	total revenue	FY2022	$860.00M – $875.00M	Reaffirmed
Feb 22, 2022	total revenue	FY2022	$860.00M – $875.00M	New
Nov 3, 2021	total revenue	FY2021	$735.00M – $740.00M	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.